Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Clinical Drug Investigation|May 26, 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
European Journal of Preventive Cardiology|February 24, 2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 12, 2021
The effects of continuous glucose monitoring system on patient outcomes and associated costs in a real-world settingNoa Triki, Naama Yekutiel, Lilly Levi, et al.
The American Journal of Cardiology|May 18, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes MellitusRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Medicine|January 15, 2021
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Journal of Perioperative Practice|February 9, 2026
Preoperative smoking cessation: Is it a trigger for long-term abstinence?Yanay Shaked, Joseph Azuri, Tomer Tzur, et al.
Neurourology and Urodynamics|April 16, 2016
Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet over-active bladder: A 4-year follow-upJoseph Azuri, Rachel Kafri, Tomer Ziv-Baran, et al.
Obesity (Silver Spring, Md.)|May 19, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Research and Theory for Nursing Practice|September 14, 2021
Ten Years Follow-Up of a Community-Nurse Managed Intervention to Improve Diabetes ControlTatyana Ginzburg, Eyal Azuri, Robert Hoffman, et al.
Diabetes, Obesity & Metabolism|December 12, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Pageof 8